Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly/Amylin Byetta clears FDA as first incretin mimetic; GSK readies Boostrix launch following May 3 BLA approval. GlaxoSmithKline’s dopamine agonist Requip (ropinirole) is approved May 4 as the first treatment for restless legs syndrome. More FDA approvals in brief